Ladenburg Thalmann Reiterates Neutral Rating for Xoma Corp. (XOMA)
Xoma Corp. (NASDAQ:XOMA)‘s stock had its “neutral” rating restated by equities research analysts at Ladenburg Thalmann in a research report issued on Wednesday.
XOMA has been the subject of a number of other research reports. Wedbush reaffirmed an “outperform” rating and set a $3.00 price objective (up previously from $1.42) on shares of Xoma Corp. in a research report on Friday, September 16th. Cowen and Company reissued a “market perform” rating on shares of Xoma Corp. in a research report on Monday, September 19th. Zacks Investment Research raised shares of Xoma Corp. from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a research report on Wednesday, October 26th. Finally, Jefferies Group reissued a “hold” rating on shares of Xoma Corp. in a research report on Friday, August 5th. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Xoma Corp. presently has a consensus rating of “Hold” and a consensus target price of $7.33.
Xoma Corp. (NASDAQ:XOMA) opened at 6.97 on Wednesday. The company has a 50 day moving average price of $3.86 and a 200 day moving average price of $1.44. Xoma Corp. has a 52-week low of $4.70 and a 52-week high of $32.40. The firm has a market capitalization of $42.02 million, a P/E ratio of 30.84 and a beta of 3.71.
Xoma Corp. (NASDAQ:XOMA) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($2.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.40) by $0.32. The company had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $1.29 million. The firm’s quarterly revenue was down 69.1% on a year-over-year basis. On average, equities analysts forecast that Xoma Corp. will post ($9.07) EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. Spark Investment Management LLC raised its stake in shares of Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares in the last quarter. Paloma Partners Management Co bought a new stake in shares of Xoma Corp. during the second quarter valued at approximately $185,000. Wedbush Securities Inc. raised its stake in shares of Xoma Corp. by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock valued at $223,000 after buying an additional 15,827 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Xoma Corp. during the first quarter valued at approximately $374,000. Finally, Vanguard Group Inc. raised its stake in shares of Xoma Corp. by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock valued at $2,934,000 after buying an additional 871,594 shares in the last quarter.
Xoma Corp. Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Stock Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related stocks with our FREE daily email newsletter.